Titan Spine closed a substantial round of financing for an undisclosed amount with its investor, Southlake Equity. Proceeds will support U.S. sales expansion and surgeon adoption of Endoskeleton® titanium interbody fusion implants and launch of next-generation nanoLOCK™ surface technology.
Titan co-founder and CEO Peter Ullrich declined to reveal how much Southlake invested in his company, but said it was roughly equal to the combined amount previously invested in Titan. According to SEC filings, the company previously raised more than $2.6 million.
Titan Spine just announced the creation of a new technology ICD-10 code for a nanotextured surface on an interbody fusion device. Titan Spine’s nanoLOCK technology has been given access to use this code, beginning 4Q16.
Titan Spine closed a substantial round of financing for an undisclosed amount with its investor, Southlake Equity. Proceeds will support U.S. sales expansion and surgeon adoption of Endoskeleton® titanium interbody fusion implants and launch of next-generation nanoLOCK™ surface technology. Update, 7/15/16: In Xconomy, Editor...
Titan Spine closed a substantial round of financing for an undisclosed amount with its investor, Southlake Equity. Proceeds will support U.S. sales expansion and surgeon adoption of Endoskeleton® titanium interbody fusion implants and launch of next-generation nanoLOCK™ surface technology.
Titan co-founder and CEO Peter Ullrich declined to reveal how much Southlake invested in his company, but said it was roughly equal to the combined amount previously invested in Titan. According to SEC filings, the company previously raised more than $2.6 million.
Titan Spine just announced the creation of a new technology ICD-10 code for a nanotextured surface on an interbody fusion device. Titan Spine’s nanoLOCK technology has been given access to use this code, beginning 4Q16.
Copy to clipboard 
